In part, the invention described herein relates generally to sutures and uses thereof in surgical procedures, including fibrin microthread sutures for surgical procedures that provide one or more of lower inflammation, reduced fibrosis, reduced scarring, and fast absorption in the host tissue.

There is provided a system for creating a fibre, the system comprising, a first tube having a first tube outlet for dispensing a first liquid composition at a first dispensing rate; a second tube having a second tube outlet for dispensing a second liquid composition at a second dispensing rate; and a rotatable collector for applying a drawing force to draw and collect the fibre, said rotatable collector being configured to rotate about its longitudinal axis that is aligned substantially parallel to a horizontal plane; wherein the first tube is positioned in proximity with respect to the second tube to allow the first liquid composition from the first tube outlet and the second liquid composition from the second tube outlet to form an interfacial polyelectrolyte complex where a fibre is to be drawn therefrom.

Provided is a leather fiber for leather spun yarn with improved physical properties of the leather spun yarn by containing leather fibers with more improved length, thickness, fineness. The leather fiber has an average length of 15 mm or more and 40% or more of the content of fibers of more than 15 mm, in the leather fibers for the leather spun yarn contained in the leather spun yarn formed by containing the leather fibers and natural fibers or/and regenerated fibers.

The present disclosure provides extruded or spun, semi-permeable, porous hollow fibres, comprising covalent ester, thioester and/or amide crosslinked polypeptides as well as processes for their production. The hollow fibres may be produced from protein, protein extracts, and/or protein isolates derived from plants, animals, bacteria, algae, archaea, and/or fungi, and in certain embodiments are intended to be suitable for human and/or animal ingestion. In some embodiments, the hollow fibres may be designed to be used in the production of cartridges that are compatible with existing and/or novel bioreactor platforms, for harbouring cell cultures in cultured meat production.

The present disclosure provides extruded or spun, semi-permeable, porous hollow fibres, comprising covalent ester, thioester and/or amide crosslinked polypeptides as well as processes for their production. The hollow fibres may be produced from protein, protein extracts, and/or protein isolates derived from plants, animals, bacteria, algae, archaea, and/or fungi, and in certain embodiments are intended to be suitable for human and/or animal ingestion. In some embodiments, the hollow fibres may be designed to be used in the production of cartridges that are compatible with existing and/or novel bioreactor platforms, for harbouring cell cultures in cultured meat production.

Fibers including a polyurethane or a protein polyurethane alloy. The fibers include a core defined by the polyurethane or the protein polyurethane alloy. The fibers including a protein polyurethane alloy include a protein dissolved within a polyurethane. In some embodiments, the fibers can be made by wet spinning a blended mixture of the polyurethane or protein polyurethane alloy and an organic solvent. In alternative embodiments, the fibers can be made by wet spinning a blended mixture of the polyurethane or protein polyurethane alloy and an aqueous polyethylene oxide solution.

Modified regenerated collagen fibers which have improved water resistance and heat resistance problematic in regenerated collagen fibers, impart heat shape memory ability, are excellent in stretchability (tenacity) and the feel of the surfaces, and have no coloring. The modified regenerated collagen fibers contain a component (A), which is vinylbenzoic acid or a salt thereof, or a polymerized product containing the component (A) as a constituent monomer in the regenerated collagen fibers.

A monolayer, plant protein based imitation leather material and methods of making same. Embodiments of the method comprise 1) creating a mixture of a one or more plant protein powder, a one or more non-proteinaceous polymer or toughening elastomer, a one or more plasticizer, a one or more cross-linking agent, and a one or more curing agent in an; 2) calendering the mixture into a flat, monolayer sheet at a controlled roll temperature and affixing the sheet onto a surface of a carrier fabric and 3) curing the calendered monolayer sheet by applying heat and pressure for a period of time.

In an embodiment, yarn comprising a plurality of fibers is provided. Each fiber may include at least 0.5% protein by weight and a synthetic polymer. Each of the plurality of fibers may be a melt-spun fiber. For each fiber, an outer portion may have a higher density of protein particles than an inner portion. Each fiber may be a skin-core fiber comprising an inner core and an outer sheath. The outer sheath of each of fiber may include at least 1% protein by weight. The inner core of each fiber may include less than 1% and/or less than 0.1% protein by weight. In another embodiment, a fabric woven from the yarn is provided. The fabric may have no or negligible discernable scroop. In other embodiments, methods of manufacture are provided.

Disclosed herein is the production of medical textile material with nanofiber surface that has transdermal drug release properties and that is coated with azithromycin active substance by using needle electrospinning method and ultrasonic spray pyrolysis (USP) technique. Specifically disclosed is a nanofiber medical textile material production method that includes the steps of preparing polymer solutions containing PVP (polyvinylpyrrolidone) with a concentration of 12 wt % and GEL (gelatin) with a concentration of 0.72 wt %; determining solution properties such as conductivity, viscosity, and surface tension, producing nanofibers from prepared polymer solutions at by atmosphere-controlled horizontal needle fiber spinning (electrospinning) setup, obtaining PVP/GEL nanofibers after the fiber spinning process, thin film coating of the drug active substance on the obtained nanofibers, PVP/GEL nanofibers by the USP method, and cross-linking of both polymers to facilitate the final application processes of the drug-release material.